NCT06592339View on ClinicalTrials.gov

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

December 29, 2022

Study Completion Date

December 29, 2022

Conditions

Hypercholesterolemia

Interventions

DRUG

MK-0616

oral administration

Trial Locations (1)

33143

QPS-MRA, LLC-Early Phase, South Miami

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY